The Biorepository Program fosters interaction and collaboration by offering an efficient, cost -effective mechanism to provide well-defined patient-derived tissues. The Biorepository Program provides opportunities to translate basic observations into clinically-relevant observations in well-characterized patient-derived materials. To accomplish this goal, the following specific services are provided:
Ileocolonic Mucosal Biopsies
Collecting From Patients With
Data Collected When Available
Dr. Edwin De Zoeten has been involved in basic immunology research for the past 17 years. When he became a Pediatric Gastroenterologist in 2004 he developed a special interest in Inflammatory Bowel Diseases (IBD). His work has progressed into the evaluation of how the immune system regulates itself in the intestine. His position as a physician scientist has allowed him to straddle two overlapping worlds providing expertise in both. His lab has the expertise in Mouse models of IBD, cell culture, protein analysis, and epigenetics, which allows him to evaluate basic immunologic questions. In addition, he has experience collecting, storing and utilizing human samples and his placement as the Scientific Director of the Pediatric IBD center allows him to have access to and develop a strong biobank.
Dr. Mark Gerich's research is focused on the pathophysiology and treatment of inflammatory bowel disease (IBD). He has been a member of the Mucosal Inflammation Program at the University of Colorado for 10 years. Over this time, he has developed a clinical database and biorepository that includes over 500 IBD patients. He has conducted research on predictors of disease outcomes, such as recurrent surgical resection in Crohn's patients, and is currently investigating the use of thromboelestography (TEG) to characterize fibrinolysis resistance in IBD patients. He has completed several studies of outcomes among IBD patients treated with unconventional therapies, including tacrolimus and thalidomide.